Pet Financial News
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Introduced at SABCS
MELBOURNE, Australia, Nov. 30, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) immediately advises that the finished Phase II OPALESCENCE investigator-initiated trial...
Pet Financial News
Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
MELBOURNE, Australia, June 26, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reveals more information of the positive arise from...
-Advertisement-
Must read
-Advertisement-